Clinical trials: Novel Coronavirus Pneumonia
COVID-19
The Use PUL-042 to Reduce the Infection Rate and Progression to COVID-19 in Adults Exposed to SARS-CoV-2
Subjects who have documented exposure to SARS-CoV-2 (COVID-19) will receive 4 doses of PUL-042 Inhalation Solution or 4 doses of a placebo solution by inhalation over 10 days.
- Trial name
- NCT04313023
- Testing
- PUL-042 Inhalation Solution
- Where
- 15 sites in United States
- Volunteers
- 217 people
- Sponsor
- Pulmotect, Inc.
Severe Acute Respiratory Syndrome Coronavirus 2
COVID-19 Related Health and Infection Control Practices Among Dentists
As dentists begin reopening their practices during a global pandemic, the risk of COVID-19 infection that dentists face in providing dental care remains unknown.
- Trial name
- NCT04423770
- Testing
- No intervention
- Where
- United States
- Volunteers
- 2,196 people, healthy volunteers welcome
- Sponsor
- American Dental Association
COVID-19, Coronavirus Infections
Safety, Tolerability, and Immunogenicity of Trivalent Coronavirus Vaccine Candidate VBI-2901a
VBI-2901a is an investigational vaccine candidate that uses enveloped virus-like particles (eVLPs) to express the spike proteins of three coronaviruses: SARS-CoV-2 (the virus that causes COVID-19 disease), SARS-CoV-1 and…
- Trial name
- NCT05548439
- Testing
- VBI-2901a
- Where
- 7 sites in Canada
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- VBI Vaccines Inc.
SARS-CoV2 Infection, Rare Diseases
Identification of Factors Associated With the Occurrence of Severe Forms of COVID-19 Infection in Patients With Inflammatory Rheumatism or Autoimmune Diseases
Factors associated with severe forms of COVID-19 infection in patients with inflammatory rheumatic diseases (IRD) or Autoimmune Diseases (AID) are unknown.
- Conditions
- SARS-CoV2 Infection, Rare Diseases, Chronic Inflammatory Rheumatism, Autoimmune Diseases
- Trial name
- CovAID (NCT05026892)
- Testing
- no intervention
- Where
- France
- Volunteers
- 1,200 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Immunocompromised Patients, SARS-CoV-2 Disease
Evaluation of Direct Antiviral Treatments Against SARS-CoV-2 in Immunocompromised Patients With Covid-19.
Due to the lower virulence of circulating Omicron variants and the high seroprevalence of anti-SARS-CoV-2 antibodies, the incidence of cases and deaths related to the SARS-CoV-2 virus has significantly decreased in recent months…
- Trial name
- COV-ID (NCT06683937)
- Testing
- Collection of data from the patient's medical file
- Where
- 18 sites in France
- Volunteers
- 327 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
COVID19
FAvipiravir and HydroxyChloroquine Combination Therapy
This study is a randomized, open-label, parallel groups multi-centered trial were participants are assigned to either an intervention arm ( a combination of Favipiravir and Hydroxychloroquin) or standard of care.
- Trial name
- FACCT (NCT04392973)
- Testing
- Favipiravir and Hydroxychloroquine
- Where
- 8 sites in Saudi Arabia
- Volunteers
- 268 people
- Sponsor
- King Abdullah International Medical Research Center
Long Covid19, Neuropsychiatric Symptom
Acupuncture for Post COVID-19 Condition (Long COVID) Neuropsychiatric Symptoms
In this study, a 12-week pragmatic, randomized, double-blinded clinical trial will be conducted to evaluate the efficacy of acupuncture for the treatment of long Covid neuropsychiatric symptoms and provide reference for clinical…
- Conditions
- Long Covid19, Neuropsychiatric Symptom, Acupuncture
- Trial name
- NCT06633666
- Testing
- Acupuncture
- Where
- Hong Kong
- Volunteers
- 160 people
- Sponsor
- Hong Kong Baptist University
COVID-19
Multicenter Clinical Study on the Efficacy and Safety of Xiyanping Injection in the Treatment of New Coronavirus Infection Pneumonia (General and Severe)
In December 2019, Wuhan, in Hubei province, China, became the center of an outbreak of pneumonia of unknown cause. In a short time, Chinese scientists had shared the genome information of a novel coronavirus (2019-nCoV) from…
- Trial name
- NCT04295551
- Testing
- Lopinavir / ritonavir tablets combined with Xiyanping injection, Lopinavir/ritonavir treatment
- Volunteers
- 80 people
- Sponsor
- Jiangxi Qingfeng Pharmaceutical Co. Ltd.
Pneumonia, Viral, Covid19
Antioxidants as Adjuvant Therapy to Standard Therapy in Patients With COVID-19
Introduction: SARS-CoV2 infection produces severe pneumonia with pulmonary alveolar collapse. There is no specific treatment to date.
- Conditions
- Pneumonia, Viral, Covid19, ARDS, Oxidative Stress
- Trial name
- ANTIOX-COVID (NCT04570254)
- Testing
- Vitamin C, Vitamin E, Melatonin
- Where
- Mexico
- Volunteers
- 110 people
- Sponsor
- Unidad Temporal COVID-19 en Centro Citibanamex
COVID-19, Long COVID
Using Data From a Multisensor Rapid Health Assessment Device to Predict Decompensation in Long COVID (AIDI)
We are conducting a research study at the VA hospital in Bedford, MA to learn more about how a multisensor rapid health assessment device, MouthLab, can help predict or anticipate future health complications in patients with…
- Trial name
- AIDI (NCT05713266)
- Testing
- MouthLabTM
- Where
- United States
- Volunteers
- 204 people, healthy volunteers welcome
- Sponsor
- Edith Nourse Rogers Memorial Veterans Hospital
SARS-CoV-2 Infection
Safety and Efficacy Study of STI-1558 in Healthy Adults and SARS-CoV-2-Positive Patients
The purpose of this study is to evaluate the safety of STI-1558 in healthy subjects and the safety, pharmacokinetics, and efficacy in SARS-CoV-2-Positive subjects.
- Trial name
- NCT05523739
- Testing
- STI-1558
- Where
- China
- Volunteers
- 79 people, healthy volunteers welcome
- Sponsor
- Zhejiang ACEA Pharmaceutical Co. Ltd.
SARS-CoV Infection, Covid19
KIDney Injury in Times of COVID-19 (KIDCOV)
There is an unmet need to evaluate the impact of sub-clinical/mild COVID19 disease in the outpatient setting on prevalent and incident renal injury, as this data is currently unavailable.
- Conditions
- SARS-CoV Infection, Covid19, Corona Virus Infection, Acute Kidney Injury
- Trial name
- KIDCOV (NCT04705766)
- Testing
- Urine Collection
- Where
- 3 sites in United States
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Viral Specific T Cell Therapy for COVID-19 Related Pneumonia
This early phase I trial identifies the feasibility, possible benefits and/or side effects of administering SARS-CoV-2 specific cytotoxic T lymphocytes (CTLs) in treating cancer patients with severe acute respiratory syndrome…
- Conditions
- Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Symptomatic COVID-19 Infection Laboratory-Confirmed
- Trial name
- NCT04742595
- Testing
- SARS-CoV-2 Antigen-specific Cytotoxic T-lymphocytes
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- M.D. Anderson Cancer Center
Covid19, Infective Pneumonia
The Effect of Inspiratory Muscle Training in Post COVID-19 Patients
The COVID-19 infection, which is considered as a pandemic by the World Health Organization, affects the whole world. COVID-19 is an infectious respiratory disease caused by SARS-CoV-2.
- Trial name
- NCT04811859
- Testing
- Inspiratory Muscle Training
- Where
- Turkey (Türkiye)
- Volunteers
- 40 people
- Sponsor
- Istinye University
Covid19
Comparison of Detection of SARS-CoV2 (COVID-19) Between Nasopharyngeal Swab Specimens and Those Obtained by Salivary Sputum
Multicenter observational study of diagnostic test validation (Research Involving the Human Person, type 3) In addition to the diagnosis by the reference method (nasopharyngeal swab), the patient will be asked to provide a saliva…
- Trial name
- COVISAL (NCT05024461)
- Testing
- Salivary test for COVID19
- Where
- French Guiana
- Volunteers
- 1,159 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier de Cayenne
Covid19, COVID-19
Tocilizumab in Coronavirus-19 Positive Patients
This is a cohort study of COVID-19 patients with hyperinflammation. It aims to determine the impact of adjunctive Tocilizumab (TCZ) to standard of care on the reduction of hyperinflammation-related mortality in COVID-19.
- Conditions
- Covid19, COVID-19, Severe Acute Respiratory Syndrome Coronavirus 2, Coronavirus
- Trial name
- NCT04423042
- Testing
- Tocilizumab
- Volunteers
- 30 people
- Sponsor
- University of Calgary
COVID-19
Human COVID-19 Immunoglobulin (COVID-HIG) Therapy for COVID-19 Patients
A randomized, double-blind, placebo-controlled phase II exploratory clinical trial to evaluate the efficacy and safety of Human COVID-19 immunoglobulin (pH4) for intravenous injection (COVID-HIG) in the treatment of patients with…
- Trial name
- NCT05173441
- Testing
- Human COVID-19 immunoglobulin (pH4) for intravenous injection
- Where
- United Arab Emirates
- Volunteers
- 180 people
- Sponsor
- Sinopharm Wuhan Plasma-derived Biotherapies Co., Ltd.
Long COVID, Long COVID Syndrome
Evaluation of MicroRNAs and Vitamin B12 Expression in Subjects with Neurologic Symptoms of Depression, Anxiety and Fatigue in Long COVID-19
At the moment, the number of people with long COVID is unkown because there is still no effective diagnosis. This is why is very important to analyze the most common symptoms, which are: depression, anxiety and fatigue.
- Trial name
- NCT06864156
- Where
- Mexico
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Instituto Nacional de Rehabilitacion
COVID-19, Vaccine Reaction
Safety and Immunogenicity of COVID-19 Vaccine Booster in Patients With Liver Diseases
Previous studies should that patients with chronic liver diseases, cirrhosis, hepatocellular carcinoma and post-liver-trasplant status had lower immunological response to SARS-CoV-2 vaccines than healthy population.
- Conditions
- COVID-19, Vaccine Reaction, Liver Diseases
- Trial name
- NMCIDCHESS2201 (NCT05204602)
- Where
- 19 sites in China
- Volunteers
- 1,000 people
- Sponsor
- Huashan Hospital
COVID-19
A COVID-19 Study to Evaluate Safety and Pharmacokinetics of COVID-HIGIV Administered in Healthy Adults
This study is designed to evaluate three dose levels of Anti-SARS-CoV-2 Immunoglobulin Intravenous (Human) (COVID-HIGIV) for safety and pharmacokinetics (PK) in healthy adults.
- Trial name
- NCT04661839
- Testing
- COVID-HIGIV
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Emergent BioSolutions
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.